174 related articles for article (PubMed ID: 35016744)
1.
Yamamoto K; Ioroi T; Shinomiya K; Yoshida A; Harada K; Fujisawa M; Omura T; Ikemi Y; Nakagawa S; Yonezawa A; Ogawa O; Matsubara K; Iwamoto T; Nishikawa K; Hayashi S; Tohara D; Murakami Y; Motoshima T; Jono H; Yano I
Oncol Res; 2022 May; 29(1):11-23. PubMed ID: 35016744
[TBL] [Abstract][Full Text] [Related]
2. [Molecular Mechanism-based Prediction of Interstitial Lung Disease Development Causedby Molecular Targeted Drugs: Association between Signal Transducer and Activator of Transcription 3 and Mammalian Target of Rapamycin inhibitor-induced Interstitial Lung Disease].
Yamamoto K
Yakugaku Zasshi; 2023; 143(11):911-916. PubMed ID: 37914338
[TBL] [Abstract][Full Text] [Related]
3. Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients.
Yamamoto K; Shinomiya K; Ioroi T; Hirata S; Harada K; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Bito T; Nishigori C; Miyake H; Fujisawa M; Hirai M
Target Oncol; 2016 Feb; 11(1):93-9. PubMed ID: 26300443
[TBL] [Abstract][Full Text] [Related]
4. STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population.
Yamamoto K; Ioroi T; Kanaya K; Shinomiya K; Komoto S; Hirata S; Harada K; Watanabe A; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Miyake H; Fujisawa M; Hirai M
Med Oncol; 2016 Mar; 33(3):24. PubMed ID: 26833481
[TBL] [Abstract][Full Text] [Related]
5. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.
Ito N; Eto M; Nakamura E; Takahashi A; Tsukamoto T; Toma H; Nakazawa H; Hirao Y; Uemura H; Kagawa S; Kanayama H; Nose Y; Kinukawa N; Nakamura T; Jinnai N; Seki T; Takamatsu M; Masui Y; Naito S; Ogawa O
J Clin Oncol; 2007 Jul; 25(19):2785-91. PubMed ID: 17602083
[TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.
Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Kozłowski W; Szczylik C
Ann Oncol; 2015 Jul; 26(7):1385-9. PubMed ID: 25962440
[TBL] [Abstract][Full Text] [Related]
7. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
8. STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.
Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S;
Eur Urol; 2013 Apr; 63(4):745-52. PubMed ID: 23063454
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
10. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk.
Cao Q; Ju X; Li P; Meng X; Shao P; Cai H; Wang M; Zhang Z; Qin C; Yin C
PLoS One; 2012; 7(11):e50302. PubMed ID: 23209702
[TBL] [Abstract][Full Text] [Related]
11. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-21 Regulates the Proliferation, Differentiation, and Apoptosis of Human Renal Cell Carcinoma Cells by the mTOR-STAT3 Signaling Pathway.
Liang T; Hu XY; Li YH; Tian BQ; Li ZW; Fu Q
Oncol Res; 2016; 24(5):371-380. PubMed ID: 27712594
[TBL] [Abstract][Full Text] [Related]
13. [Spontaneous Remission of Everolimus-Induced Interstitial Lung Disease in Metastatic Renal Cell Carcinoma : An Autopsy Case Report].
Kurokawa M; Naito S; Ichiyanagi O; Kabasawa T; Kurota Y; Sakurai T; Nishida H; Kawazoe H; Kato T; Nagaoka A; Yamakawa M; Tsuchiya N
Hinyokika Kiyo; 2017 Sep; 63(9):377-380. PubMed ID: 28992668
[TBL] [Abstract][Full Text] [Related]
14. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma.
Hagiwara N; Watanabe M; Iizuka-Ohashi M; Yokota I; Toriyama S; Sukeno M; Tomosugi M; Sowa Y; Hongo F; Mikami K; Soh J; Fujito A; Miyashita H; Morioka Y; Miki T; Ukimura O; Sakai T
Cancer Lett; 2018 Sep; 431():182-189. PubMed ID: 29778569
[TBL] [Abstract][Full Text] [Related]
15. Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors.
Rua Fernández OR; Escala Cornejo R; Navarro Martín M; García Muñoz M; Antunez Plaza P; García Dominguez AR; Cruz Hernández JJ
Urology; 2018 Jul; 117():41-43. PubMed ID: 29702156
[TBL] [Abstract][Full Text] [Related]
16. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
17. [Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report].
Utsunomiya N; Kono Y; Matsumoto K; Matsumoto T; Nakagawa A; Tsunemori H; Okada T; Muguruma K; Kawakita M
Hinyokika Kiyo; 2014 Jan; 60(1):25-8. PubMed ID: 24594769
[TBL] [Abstract][Full Text] [Related]
18. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; Molinié V; Escudier B
Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model.
Shanmugam MK; Rajendran P; Li F; Kim C; Sikka S; Siveen KS; Kumar AP; Ahn KS; Sethi G
Mol Carcinog; 2015 Oct; 54(10):971-85. PubMed ID: 24797723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
